However, establishing the causal molecular mechanisms by which genetic variants affect RA phenotypes or differential response to TNF-α blocker to inform rational selection of molecular intervention targets for RA remains a challenging problem. The gene discussed is TNF; the disease is rheumatoid arthritis.